StudyFinder

A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors with Azirkitug as a Single Agent and in Combination(s) with Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Status: Recruiting

This trial will evaluate whether azirkitug (ABBV-514) as monotherapy and in combination with budigalimab (ABBV-181) or bevacizumab is safe and tolerable for people with locally advanced or metastatic solid tumors.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• may not be able to do strenuous activity but able to walk and do work of a light or sedentary nature, e.g., light house work, office work
• advanced or metastatic cancer who have previously been treated
• see link to clinicaltrials.gov for complete Inclusion Criteria
Exclusion Criteria:

• active autoimmune or immunodeficiency disease
• women who are pregnant
• significant heart disease
• see link to clinicaltrials.gov for complete Exclusion criteria
Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Colorectal Cancer, Gastric/Esophageal Cancer, Head and Neck Carcinoma, Serous Ovarian Cancer

Study Contact: Naomi Fujioka - fujio002@umn.edu
Principal Investigator: Naomi Fujioka
Phase: PHASE1
IRB Number: STUDY00026235
See this study on ClinicalTrials.gov

Back